Discontinuation of Jurnista®

HPS Pharmacies wish to advise that Janssen-Cilag are planning to discontinue all Jurnista^® prolonged-release tablets as follows:

Jurnista^® Prolonged-Release Tablets
Hydromorphone hydrochloride 4mg
ARTG 155995

Jurnista^® Prolonged-Release Tablets
Hydromorphone hydrochloride 8mg
ARTG 141508

Jurnista^® Prolonged-Release Tablets
Hydromorphone hydrochloride 16mg
ARTG 141533

Jurnista^® Prolonged-Release Tablets
Hydromorphone hydrochloride 32mg
ARTG 141534

Jurnista^® Prolonged-Release Tablets
Hydromorphone hydrochloride 64mg
ARTG 141535

Discontinuation of supply will occur in Australia from 30 April 2023 (and/or until supplies are exhausted).

Janssen advises that the discontinuation of Jurnista^® was a business decision and is not related to any safety, efficacy or quality issues.

Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Janssen on 1800 226 334, or your pharmacist at HPS Pharmacies.

Download PDF